Top-News

H. Lundbeck News

Keine aktuellen Kursdaten verfügbar
WKN: 922351
ISIN: DK0010287234
US-Symbol: HLUKF
Typ: Aktie

Unternehmensmeldungen

26.11.19 - DGAP
Chelverton UK Dividend Trust plc: Net Asset Value
Chelverton UK Dividend Trust plc (SDV) Chelverton UK Dividend Trust plc: Net Asset Value 26-Nov-2019 / 17:21 GMT/BST Dissemination of a Regulatory Announcement, transmitted ...
07.03.13 - DGAP
OTSUKA ADVANCING RAPIDLY IN CENTRAL NERVOUS SYSTEM DISORDERS - OTSUKA AND LUNDBECK EXPANDING THEIR EXISTING COLLABORATION
H. Lundbeck A/S 07.03.2013 07:00 --------------------------------------------------------------------------- Valby, 2013-03-07 07:00 CET (GLOBE NEWSWIRE) -- -- Otsuka and Lundbeck expand ...
07.09.11 - Hugin
Marie-Laure Pochon elected as Lundbeck's new EVP of Commercial Operations
Lundbeck's Executive Management Group reduced from six to four members H. Lundbeck A/S (Lundbeck) announces the appointment of Marie-​Laure Pochon as new Executive Vice ...
22.08.11 - Hugin
Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. ...
22.08.11 - Hugin
Launch of Lexapro commenced in Japan
* Lexapro(®) - the most prescribed branded antidepressant in the world - now also available to Japanese patients * Clinical phase III studies in Japan have confirmed the positive ...
15.08.11 - Hugin
Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. ...
10.08.11 - Hugin
First half report 2011 - The solid momentum continues. Expected full year results to be in the upper end of the guidance range
H. Lundbeck A/S (Lundbeck) reports second quarter revenue of DKK 4,100 million growing 9% compared to the same period last year. In constant exchange rates revenue for the ...
15.06.11 - Hugin
Nalmefene completes clinical phase III programme - submission of the European Marketing Authorization Application (MAA) is expected by the end of 2011
* Lundbeck has now completed the second 6-months efficacy study in the overall clinical phase III programme with nalmefene * Nalmefene has a significant potential for helping ...
10.06.11 - Hugin
Lundbeck announces that Stig Løkke Pedersen, Executive Vice President, Commercial Operations, resigns
H. Lundbeck A/S (Lundbeck) today announced that Stig Løkke Pedersen, EVP for Commercial Operations, has decided to resign from his position at Lundbeck in order to pursue ...
06.06.11 - Hugin
Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. ...
31.05.11 - Hugin
Update on Lundbeck's total number of voting rights and total share capital
H. Lundbeck A/S (Lundbeck) today publishes the total number of voting rights and total share capital in the company cf. section 6 of the Executive Order on Issuers' Disclosure ...
01.02.11 - Hugin
Annual general meeting at H. Lundbeck A/S
H. Lundbeck A/S' annual general meeting will be held on 30 March 2011. Shareholders who would like to have specific issues on the agenda for the annual general meeting must ...
20.01.11 - Hugin
The clinical phase III programme commenced on zicronapine
* Based on the solid outcome from the clinical phase II studies, the clinical phase III programme has now been initiated * The first study is a risperidone-​controlled fixed-​dose study ...
03.01.11 - Hugin
First two clinical phase III studies confirm the profile of nalmefene as efficacious and safe in helping individuals to reduce their alcohol consumption
* Lundbeck has completed a short-​term efficacy study and a long-term safety study in the overall pivotal programme with nalmefene * The pivotal programme also includes an ...
16.12.10 - Hugin
Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis
H. Lundbeck A/S (Lundbeck) today announced that it has signed agreements with Zenobia Therapeutics (Zenobia) and Vernalis plc (Vernalis) which will provide Lundbeck with ...
14.12.10 - Hugin
Lundbeck to establish a strong, dedicated sales force behind Lexapro® in China as part of a new co-promotion agreement
* Lundbeck will substantially increase sales and marketing efforts behind Lexapro(®) in China * Lundbeck already has a foothold in China and stands to benefit from the rapidly ...
04.12.10 - Hugin
Lundbeck reports positive phase III study results for clobazam in the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome
* Data from the pivotal clobazam study were presented at the American Epilepsy Society meeting in San Antonio, TX * Two highest dosages of clobazam as add-on therapy achieved ...
23.11.10 - Hugin
Financial calendar 2011
H. Lundbeck A/S has planned the following dates in 2011 for the financial statements, the Annual General Meeting and payment of annual dividend. 24 February 2011              Annual ...
04.11.10 - Hugin
Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. ...
03.11.10 - Hugin
Third quarter report 2010 -- Continued strong growth in third quarter - 2010 results to be at the high end of guidance range
H. Lundbeck A/S (Lundbeck) reports third quarter revenue of DKK 3,619 million, an increase of 7% compared to the third quarter results of 2009. Profit from operations (EBIT) was ...

Newssuche

Videos

newspaper
26.04.24 +10,71%
Technical Trading: Gold Long freitags
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »